Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats.
BACKGROUND
Food intake and energy expenditure are the two main determinants of body weight. Given that 5-HT(2C) receptor agonists are reported to have effects on both energy expenditure and food intake, this strongly suggests that 5-HT(2C) receptor agonists have excellent potential for development as antiobesitiy drugs. One important issue in antiobesity drug development is whether the effects of the compound are maintained during chronic drug treatment.


OBJECTIVE
The purpose of the present study was to investigate the effect of repeated oral administration of three 5-HT(2C) receptor agonists, m-chlorophenylpiperazine (mCPP), d(S)-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine (RO60-0175) and (S)-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine (YM348), on food intake and energy expenditure in rats.


RESULTS
In the food intake study, mCPP, RO60-0175 and YM348 decreased food intake in a dose-dependent manner on day 1 of administration. On day 14 of repeated administration, the hypophagic effect of YM348 was lost and that of mCPP was reduced. In contrast, the hypophagic effect of RO60-0175 was maintained even after repeated administration. The hypophagic effects of all agonists were significantly inhibited by a 5-HT(2C) receptor antagonist, SB242084. In contrast to the hypophagic effects, no drug tolerance developed with respect to the hyperthermic effects of mCPP, RO60-0175, and YM348. The hyperthermic effects of these drugs were also inhibited by SB242084.


CONCLUSIONS
Together, the difference between compounds in their hypophagic effects and the similarity in their hyperthermic effects suggest a diversity in agonists in 5-HT(2C) receptor-mediated weight control in rats.
Hayashi
Aska
A
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd, 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. hayashi.asuka@yamanouchi.co.jp
Suzuki
Masanori
M
Sasamata
Masao
M
Miyata
Keiji
K
D000284:Administration, Oral; D000631:Aminopyridines / Q000494:pharmacology; D000818:Animals; D001067:Appetite Depressants / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004734:Energy Metabolism / Q000187:drug effects*; D005021:Ethylamines / Q000494:pharmacology; D005247:Feeding Behavior / Q000187:drug effects*; D007191:Indazoles; D007211:Indoles / Q000494:pharmacology; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D058826:Serotonin 5-HT2 Receptor Agonists; D015431:Weight Loss / Q000187:drug effects*
C107820:6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indoline; D000631:Aminopyridines; D001067:Appetite Depressants; D005021:Ethylamines; D007191:Indazoles; D007211:Indoles; D010879:Piperazines; C103848:Ro 60-0175; D058826:Serotonin 5-HT2 Receptor Agonists; C488691:YM348; C015068:1-(3-chlorophenyl)piperazine
Physiol Behav. 1982 Sep;29(3):553-9
7178261
Neuropharmacology. 2001 Aug;41(2):200-9
11489456
Neuropharmacology. 1997 Feb;36(2):233-9
9144661
J Pharmacol Exp Ther. 1998 Aug;286(2):913-24
9694950
Trends Pharmacol Sci. 1995 Jul;16(7):232-8
7667897
Neuropharmacology. 1994 Mar-Apr;33(3-4):261-73
7984266
Psychopharmacology (Berl). 2000 Oct;152(3):256-67
11105935
Br J Pharmacol. 1988 May;94(1):137-47
3401632
Neuropharmacology. 1994 Mar-Apr;33(3-4):275-317
7984267
J Pharmacol Exp Ther. 1994 Oct;271(1):143-8
7965707
Biochem Pharmacol. 2001 Aug 15;62(4):431-8
11448452
J Neurosci. 2000 Nov 15;20(22):8637-42
11069973
Trends Pharmacol Sci. 1998 Jul;19(7):270-6
9703760
Biochem Biophys Res Commun. 2002 Jul 12;295(2):249-54
12150939
Clin Ther. 2003 Jan;25(1):58-80
12637112
Mol Pharmacol. 1998 Jul;54(1):94-104
9658194
J Pharmacol Exp Ther. 2002 Sep;302(3):957-62
12183652
Mol Endocrinol. 1994 Apr;8(4):518-27
7914350
Brain Res. 2004 Jun 18;1011(2):221-7
15157808
Diabetes Obes Metab. 2000 Jun;2(3):175-87
11220553
Neuropharmacology. 1999 Aug;38(8):1083-152
10462127
Eur J Pharmacol. 1995 Dec 7;293(4):309-17
8748683
Int J Obes Relat Metab Disord. 1999 Jul;23(7):669-77
10454099
J Biol Chem. 1997 Jul 11;272(28):17686-93
9211919
Pharmacol Biochem Behav. 1988 Jun;30(2):451-6
2971978
Br J Pharmacol. 1998 Apr;123(8):1707-15
9605579
Psychopharmacology (Berl). 2003 May;167(3):274-80
12690422
Eur J Pharmacol. 2004 Jan 1;483(1):37-43
14709324
Br J Pharmacol. 1998 Oct;125(4):727-34
9831908
Brain Res Bull. 1982 Jun;8(6):645-51
7139357
Psychopharmacology (Berl). 2001 Sep;157(3):292-8
11605085
Am J Physiol. 1989 Dec;257(6 Pt 2):R1322-7
2690646
Psychopharmacology (Berl). 1996 Feb;123(4):333-9
8867872
Nature. 1995 Apr 6;374(6522):542-6
7700379
Eur J Pharmacol. 2000 Jan 10;387(2):197-204
10650160
Science. 2002 Jul 26;297(5581):609-11
12142539
Br J Pharmacol. 1998 Jun;124(4):763-71
9690869
Br J Pharmacol. 2000 Jul;130(6):1305-14
10903970
Arch Intern Med. 2000 Jul 24;160(14):2185-91
10904462
Psychopharmacology (Berl). 1988;96(1):93-100
2906446
Pharmacol Biochem Behav. 2000 Oct;67(2):291-305
11124393
J Neurochem. 1995 Jun;64(6):2473-9
7760026